The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

The Department of Science and Technology (DOST), in partnership with the Nueva Vizcaya State University (NVSU), opened the ...

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing ...

Wide Mineralized Intersection: The second RPM discovery hole (AN-24-03) returned an average of 0.25% nickel and 0.29% ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene ... via intravesical instillation using Ractigen's proprietary LiCO™ delivery technology, RAG-01 ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

The wider tau-targeting pipeline meanwhile includes a handful of phase 3 candidates, including Eisai's antibody-based E-2814 and small-molecule drugs from Annovis Bio (buntanetap), BioVie ...

DAX Futures 22917.00-161.00-0.70% ...